Ophthalmology Times

01/27/2026

Researchers from the Bascom Palmer Eye Institute in Miami found that instillation of pilocarpine hydrochloride ophthalmic solution 0.4% (Qlosi; Orasis Pharmaceuticals, Ltd) resulted in a significant reduction in pupillary diameter with minimal impact on lens thickness and ciliary muscle accommodation in presbyopic eyes.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

01/26/2026

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

01/26/2026

Patient awareness of glaucoma differs markedly depending on urban and rural locations and the patient population, and that awareness or lack thereof impacts diagnosis, treatment, and monitoring.

James Tsai, MD, MBA, discussed with Ophthalmology Times his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can run the gamut from highly educated patients to uninformed individuals.

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

01/25/2026

2026 from an OD's perspective: What is on the horizon

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

01/25/2026

The future of glaucoma treatment is bright. James Tsai, MD, MBA, shed light on what is in the offing for glaucoma specialists. He is president of the New York Eye and Ear Infirmary of Mount Sinai, the Delafield-Rodgers Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai, and chair of the Department of Ophthalmology at the Mount Sinai Health System, all in New York.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

01/24/2026

The US Food and Drug Administration has authorized a single-patient expanded access (compassionate use) Investigational New Drug (IND) application for the use of urcosimod (0.05%) in a patient with neuropathic corneal pain (NCP). The application was submitted by Pedram Hamrah, MD, vice chair of academic medicine, Department of Ophthalmology, University of South Florida.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

01/23/2026

Clinical nuance matters when optimizing retinal care. In this Ophthalmology Times Viewpoints program, Sharon Fekrat, MD, FACS, FASRS, moderates a panel of Jorge Fortun, MD, and John Kitchens, MD, as they explore how differences in disease mechanisms and treatment goals across neovascular AMD, DME, and RVO influence anti-VEGF strategy.

See how leading experts are translating these insights into real-world decision-making: https://hubs.li/Q03_y-FQ0

01/22/2026

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

The BIM-IOL System consists of 2 non-bioerodible drug pads attached to the optic-haptic junction of a monofocal intraocular lens (IOL), which is implanted as part of routine cataract surgery.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

01/21/2026

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the Pfizer-BioNTech (BNT162b2) COVID-19 mRNA vaccine concluded that changes in corneal endothelium were seen in the short term after 2 doses.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

01/20/2026

In this Q&A conversation, the Eye Care Network spoke with David S. Boyer, MD, about how his approach to GA has evolved, including the role of multimodal imaging, interpretation of clinical trial and real-world data, management of treatment-related risks, and expectations for future therapeutic options.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

01/19/2026

After the termination of the proposed acquisition by Alcon, STAAR has announced changes to its board of directors in a cooperation agreement with Broadwood Partners.

Broadwood Partners and its affiliates are the largest private stockholders in STAAR, owning 31% of STAAR’s outstanding common stock. Since the proposed deal between Alcon and STAAR was announced in August 2025, Broadwood has steadily opposed the merger and adamantly claimed the sale was being done at the wrong time and price, as well as the process having major flaws.

Broadwood and Yunqi Capital will add 3 total members to the board, while the CEO and more step down.

01/18/2026

An editorial published in the New England Journal of Medicine referred to the Photovoltaic Retina Implant Microarray (PRIMA) Implant (Science Corporation) as “the first treatment to restore vision” in patients with advanced geographic atrophy (GA) associated with age-related macular degeneration (AMD).

The editorial highlights the study by Holz and colleagues2 printed in the same issue of the journal. The authors reported the 12-month results achieved in patients with severe visual loss from GA secondary to AMD.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.